Diabetes Mellitus, Type 2
Conditions
Brief summary
This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.
Interventions
DRUGInsulin detemir
No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis (ever) of type 2 diabetes * Prescription (ever) of basal insulins glargine or detemir * Insulin-naïve until initiation of basal insulins glargine or detemir * Aged 40 years or older at start of observation period
Exclusion criteria
* Diagnosis of type 1 diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Age at all cause death or censoring | Observation period 2004 - 2018 | Years |
| Age at death of cardiovascular disease | Observation period 2004 - 2018 | Years |
Countries
Denmark
Outcome results
None listed